Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

Ivermectin has anti-inflammatory properties that could be beneficial in treatment of T-cell mediated skin inflammatory diseases

Ivermectin Has Topical Anti-Inflammatory Properties

0
Topical ivermectin improves allergic skin inflammation in murine model of atopic dermatitis
Pyridoxine-doxylamine (Diclectin)

Data on Effectiveness of Morning Sickness Drug May Be Flawed

0
Original unpublished 1970s study results on pyridoxine-doxylamine may be deficient, authors say
For patients with advanced unresectable hepatocellular carcinoma

Sorafenib Effect on HCC Survival Depends on Hepatitis Status

0
Findings in meta-analysis of individual patient data for advanced unresectable hepatocellular carcinoma
From 2000 to 2011 there were shifts in the treatment of advanced-stage non-small-cell lung cancer

2000 to 2011 Saw Shift in Treatment for Advanced NSCLC

0
Rise in use of pemetrexed, erlotinib, bevacizumab; longest treatment duration with these agents
For high-risk women

Letrozole Tops Aspirin for Halting Ovarian Hyperstimulation

0
Decreases incidence of moderate and severe early-onset ovarian hyperstimulation syndrome
After metformin failure

Sequential Empagliflozin, Linagliptin Diabetes Tx Effective

0
Glucose control most probably mediated by effects on alpha- and beta-cell function
Fenofibrate therapy may reduce cardiovascular disease in statin-treated patients with diabetes and dyslipidemia

Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia

0
No reduction in primary outcome for 4,644 ACCORD participants followed for median of 9.7 years
For patients with chronic kidney disease

Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

0
Reduced all-cause death for chronic kidney disease, congestive heart failure, chronic liver disease
The American College of Physicians has updated recommendations on the oral pharmacologic treatment of type 2 diabetes in adults. The clinical practice guideline update was published online Jan. 3 in the Annals of Internal Medicine.

ACP Updates Recommendations for Oral Medications in T2DM

0
Recs serve as update to 2012 American College of Physicians guideline
Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer

Zoledronic Acid Every 12 Weeks Noninferior in Bone Metastases

0
No increase in risk of skeletal events versus treatment every four weeks for bone metastases